Abivax clears FDA pre-NDA meeting for obefazimod in ulcerative colitis
Abivax has completed a pre-New Drug Application meeting with the US Food and Drug Administration for obefazimod in moderately to severely active ulcerative colitis, with the agency providing constructive feedback that the company says aligns with its planned submission strategy. The dual-listed biotech (Euronext Paris / Nasdaq: ABVX) remains on course to lodge its first NDA before the end of 2026.
The pre-NDA meeting is a formal consultation step in which companies seek FDA guidance on the content, format and completeness of a planned submission before it is filed. A constructive outcome does not guarantee approval, but it reduces the risk of a refuse-to-file decision and signals that the agency has no fundamental objections to the package being assembled. Abivax said the FDA's feedback specifically supported the planned content and format of the dossier.
Building on Phase 3 data
The NDA will be anchored by results from the ABTECT Phase 3 programme, which Abivax said returned positive findings earlier in 2026. The company did not re-release the underlying data in this announcement, but has previously described ABTECT as a two-part study covering induction and maintenance of remission in adult UC patients.
Marc de Garidel, chief executive of Abivax, said the FDA alignment "reinforces our confidence in the path toward filing" and described the pre-NDA outcome as an important milestone. He credited the ABTECT results as continuing to support obefazimod's potential in the indication.
Obefazimod, also known as ABX464, is a small-molecule compound that the company says works by modulating the body's natural immune regulatory mechanisms rather than broadly suppressing immune function. Abivax has positioned it as a differentiated oral therapy for inflammatory bowel disease, though the precise mechanism details remain a subject of ongoing scientific discussion.
Market context and competitive landscape
Ulcerative colitis is an active and crowded therapeutic area. Approved biologics including anti-TNF agents, anti-integrin vedolizumab and anti-IL-12/23 ustekinumab are well established, while a newer generation of oral therapies has been gaining ground. The JAK inhibitor class, represented by tofacitinib, upadacitinib and filgotinib, has reshaped prescribing patterns in moderate-to-severe UC over the past several years, and S1P receptor modulators have expanded the oral treatment menu further.
Obefazimod, if approved, would enter as a small-molecule oral agent competing in that same convenience-oriented segment. Its differentiation story rests on its claimed tolerability profile and novel mechanism, though payers and clinicians will require head-to-head or indirect comparison data to judge its place in sequencing decisions.
From a regulatory standpoint, the FDA has been broadly supportive of UC submissions backed by rigorous Phase 3 programmes that use standardised endoscopic and clinical endpoints. Abivax will need to demonstrate that the ABTECT package meets those evidentiary standards in full. A year-end 2026 NDA submission, if filed as planned, would put a potential PDUFA review date in the second half of 2027, assuming a standard ten-month review cycle.
Abivax is a Franco-American company with operations in Paris and the United States. Obefazimod is its sole clinical-stage asset and the NDA filing represents the company's most consequential near-term milestone.